Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive … (NCT04801914) | Clinical Trial Compass
UnknownNot Applicable
Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia Before and After PTBD
Serbia30 participantsStarted 2020-12-11
Plain-language summary
The purpose of this study is to detect differences in the enzymatic activity of matrix metalloproteinases in patients with malignant obstructive hyperbilirubinemia before and after percutaneous biliary drainage.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
pathological confirmation or imaging data confirming malignant disease causing bile duct obstruction, performance status 0-1
Exclusion Criteria:
terminally ill patients, performance status \>2, hepatic decompensation, severe underlying cardiac or renal diseases and coagulation disorders.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is measuring MMP-2 and MMP-9 enzyme activity in blood before and after a drainage procedure called PTBD — can you explain what these enzymes might tell us about my condition and why tracking them could matter for my care?
2Since this trial doesn't have a standard phase listed and its recruitment status is unknown, does that mean it's still actively enrolling patients, and would my situation even be relevant to what the researchers are looking for?
3The study involves a procedure called percutaneous transhepatic biliary drainage (PTBD) — is that something already being considered as part of my treatment, or would participating in this research change the procedures I'd otherwise receive?
4This appears to be an observational study focused on blood enzyme measurements, so what would actually be different for me as a participant compared to receiving standard care for malignant obstructive jaundice?
5Given that the recruitment status is listed as unknown, would you be able to find out whether this study is still running and whether the findings so far have revealed anything useful about how MMP levels relate to outcomes in patients like me?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
MMP-2 and MMP-9 serum activity
Timeframe: during intervention
Trial details
NCT IDNCT04801914
SponsorInstitut za Rehabilitaciju Sokobanjska Beograd